Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering novel therapies for neurodegenerative diseases. Recent clinical trials of the company’s lead compound yielded encouraging results, with buntanetap shown to improve cognition in both Alzheimer’s and Parkinson’s patients. The company also introduced a new crystalline form of buntanetap with improved properties, “offering significant advantages over the less structured, old semi-crystalline form,” according to a recent article.
“Annovis filed the new crystalline form with the International Patent Cooperation Treaty and a provisional patent for the manufacturing of this crystalline form, covering the entire synthesis process. The company also received approval from the Food and Drug Administration to continue the clinical development with this new form of buntanetap. Additionally, the company was granted a U.S. patent for the use of buntanetap in the treatment of acute traumatic brain injury, expanding its coverage, since acute indication claims had been previously granted in Europe and worldwide,” the article reads. “These milestones position us strongly as we move closer to providing much-needed treatments to patients,” said Annovis Bio Founder, President and CEO Maria L. Maccecchini, Ph.D.
To view the full article, visit https://ibn.fm/MOslN
About Annovis Bio Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.
For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN